25 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 02:22
  [Comment] Diabetes registries and high-quality diabetes care - Kamlesh Khunti, Chantal Mathieu, Bart Torbeyns, Stefano Del Prato, Robert Heine, EUDF Strategic Forum Data and Registries Lancet Diab Endocrinol
  Diabetes registries have been established in many countries following recommendations of the St Vincent Declaration to help improve quality of care for diabetes.1 Diabetes registries can help measure and compare outcomes, and highlight variations in care for quality improvement. Well (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Correspondence] Insulin products and patents in the USA in 2004, 2014, and 2020: a cross-sectional study - Victor L Van de Wiele, Aaron S Kesselheim, David Beran, Jonathan J Darrow Lancet Diab Endocrinol
  To treat diabetes, one of the most prevalent diseases globally and in the USA,1 the US Food and Drug Administration (FDA) has approved a wide range of synthetic insulin products since the early 1980s. Despite this range of products, access to insulin remains challenging in part due to product (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [In Focus] May Ng: a lifetime commitment to children - Carl Power Lancet Diab Endocrinol
  May Ng says that, growing up in Malaysia, she always knew what she wanted to be: “As a small child, I would say paediatrician, not doctor”. She loved looking after her younger sister and cousins. Ng has turned her affection for children into a (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [In Focus] Diabetes educators: rewriting the narrative - Marta Koch, Parizad Avari Lancet Diab Endocrinol
  “We are a large family”, agree Prashanth Mani, Lakshminarayana Varimadugu, and Sridhar Rajamohan, who are diabetes educators in India and who live with type 1 diabetes themselves. Diabetes care in low-income and middle-income countries (LMICs) entails many challenges. Delayed diagnosis, (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 859–68 Lancet Diab Endocrinol
  Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Articles] Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial - Margaretha M Visser, Sara Charleer, Steffen Fieuws, Christophe De Block, Robert Hilbrands, Liesbeth Van Huffel, Toon Maes, Gerd Vanhaverbeke, Eveline Dirinck, Nele Myngheer, Chris Vercammen, Frank Nobels, Bart Keymeulen, Chantal Mathieu, Pieter Gillard Lancet Diab Endocrinol
  Glycaemic control and hypoglycaemia worry improved significantly up to 24 months after switching from isCGM without alerts to rtCGM with alerts, supporting the use of rtCGM in the care of adults with type 1 diabetes. (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Editorial] The voices of lived experience in diabetes and endocrinology - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Patients are at the heart of medicine. Thankfully, the world is filled with caring professionals who both improve and save lives every day, despite the incredible pressures that they and health systems are under. There is also some reassurance and comfort in knowing that most health-care (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 02:22
  [Comment] Clinical use of continuous glucose monitoring in type 1 diabetes - Kirsten Nørgaard, Ulrik Pedersen-Bjergaard Lancet Diab Endocrinol
  Advances in diabetes technology over the past 2 decades have provided treatment solutions that are now widely adopted in the management of type 1 diabetes. One such example is the integration of continuous glucose monitoring (CGM) systems as part of the standard of care for type 1 diabetes.1 (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))

12 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Hot topics on insulin access: pricing in the USA - Talha Burki Lancet Diab Endocrinol
  It is difficult to know how many Americans ration their insulin. But it is fair to assume that the practice is widespread. In 2021, as part of the National Health Interview Survey, American adults who use insulin were asked whether they had skipped doses, taken less than they needed, or delayed (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))

7 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Teplizumab approval for type 1 diabetes in the USA - Carmella Evans-Molina, Richard A. Oram Lancet Diab Endocrinol
  On Nov 17, 2022, the US Food and Drug Administration (FDA) approved teplizumab as the first disease-modifying therapy in type 1 diabetes. The approval of teplizumab to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older is the culmination of nearly 20 years (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Correspondence] Teplizumab approval for type 1 diabetes in the USA - David Beran, Carol Abidha, Amanda Adler, Carine de Beaufort, Molly Lepeska, Naomi Levitt, Elizabeth Pfiester, Jessica H Zafra-Tanaka, Edwin AM Gale Lancet Diab Endocrinol
  The US Food and Drug Administration's (FDA) approval of teplizumab to delay the onset of type 1 diabetes1 could be seen as symbolic, because it came a century after the first use of insulin. Teplizumab, an anti-CD3 monoclonal antibody, is now approved in the USA for people at high risk of type (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Comment] Blood lipids after COVID-19 infection - Paul Durrington Lancet Diab Endocrinol
  Atherosclerotic cardiovascular disease incidence is increased both during acute COVID-19 infection and for an indefinite period afterwards.1,2 For this reason it has been recommended that lipid-lowering medication is generally continued throughout the period of active infection and (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Correspondence] Teplizumab approval for type 1 diabetes in the USA - Olga Kordonouri, Felix Reschke, Thomas Danne Lancet Diab Endocrinol
  Since its approval by the US Food and Drug Administration (FDA) in November, 2022, teplizumab is the first available drug shown to delay the onset of clinical symptoms of type 1 diabetes (stage 3).1 Teplizumab, therefore, offers the possibility of intervening in early stage (stage 2) type 1 (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Articles] Risks and burdens of incident dyslipidaemia in long COVID: a cohort study - Evan Xu, Yan Xie, Ziyad Al-Aly Lancet Diab Endocrinol
  Our findings suggest increased risks and 1-year burdens of incident dyslipidaemia and incident lipid-lowering medications use in the post-acute phase of COVID-19 infection. Post-acute care for those with COVID-19 should involve attention to dyslipidaemia as a potential post-acute sequela of (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Articles] Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open?label, multinational, randomised, controlled, non-inferiority trial - Elisabeth R Mathiesen, Amra Ciric Alibegovic, Rosa Corcoy, Fidelma Dunne, Denice S Feig, Moshe Hod, Ting Jia, Balamurali Kalyanam, Soumitra Kar, Alexandra Kautzky-Willer, Cassio Marchesini, Rustam D Rea, Peter Damm, EXPECT study group Lancet Diab Endocrinol
  In pregnant women with type 1 diabetes, degludec was found to be non-inferior to detemir. (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Comment] Insulin regimens during type 1 diabetes pregnancy - Helen R Murphy Lancet Diab Endocrinol
  The safety of insulin and all diabetes treatments in early pregnancy, particularly during the first 40 days after conception, is paramount.1,2 However, few insulin (or diabetes device) manufacturers rigorously evaluate newer diabetes treatments before and during pregnancy. In The Lancet (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))

6 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial - Kausik K Ray, Roel P T Troquay, Frank L J Visseren, Lawrence A Leiter, R Scott Wright, Sheikh Vikarunnessa, Zsolt Talloczy, Xiao Zang, Pierre Maheux, Anastasia Lesogor, Ulf Landmesser Lancet Diab Endocrinol
  Twice-yearly inclisiran provided sustained reductions in LDL cholesterol and PCSK9 concentrations and was well tolerated over 4 years in the extension study. This is the first prospective long-term study to assess repeat hepatic exposure to (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Comment] ORION-3: delivering lipid lowering treatment for longer - Stephen J Nicholls Lancet Diab Endocrinol
  The importance of LDL cholesterol in atherosclerotic cardiovascular disease (ASCVD) is highlighted by countless studies establishing its role in disease causality and clinical trials showing a direct association between lowering LDL cholesterol and reductions in cardiovascular risk. Although (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))

24 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 12:40
  [Editorial] Migrant health: a global responsibility - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  December 18 marks the 22nd International Migrants Day and more people than ever are living in a country outside of their country of birth. According to The International Organisation for Migration (IOM) 2022 report, close to 4% of the world's population in 2020 were migrants, three times the (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [Comment] Predicting the response to GLP-1 receptor agonists: an unexpected role for ?-arrestin-1 - Robert Sladek Lancet Diab Endocrinol
  Drugs targeting glucagon-like peptide 1 (GLP-1) and its heterotrimeric G protein-coupled receptor (GPCR) are important therapies for type 2 diabetes.1 GLP-1 is an incretin hormone which potentiates glucose-stimulated insulin secretion after meals. After binding to its receptor on ? cells (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [Correspondence] Mendelian randomisation and vitamin D: the importance of model assumptions - George Davey Smith Lancet Diab Endocrinol
  There are issues of concern raised by analyses presented by the Emerging Risk Factors Collaboration, EPIC-CVD, and Vitamin D Studies Collaboration in “Estimating dose-response relationships for vitamin D with cardiovascular mortality, stroke, and all-cause mortality: observational and Mendelian (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [Correspondence] Mendelian randomisation and vitamin D: the importance of model assumptions - Guillaume Butler-Laporte, J Brent Richards Lancet Diab Endocrinol
  In a previous issue of the journal, we had commented1 on the use of a novel Mendelian randomisation method that tested for non-linear effects of vitamin D and its measured metabolite 25-hydroxyvitamin D (25[OH]D), on diseases, as reported by the Emerging Risk Factors Collaboration, EPIC-CVD, (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [Correspondence] Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply - Stephen Burgess, Angela M Wood, Adam S Butterworth Lancet Diab Endocrinol
  As noted by George Davey Smith and Guillaume Butler-Laporte and J Brent Richards, our recent paper exploring genetic evidence for an effect of vitamin D supplementation on major health outcomes showed associations between a genetic score that predicts 25-hydroxyvitamin D (25[OH]D) (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [In Focus] Silver Bahendeka: the obligation to hope - Carl Power Lancet Diab Endocrinol
  To say that Silver Bahendeka had humble beginnings is an understatement. He grew up in Mushanga, a remote village in the south-west of Uganda, one of the poorest nations in the world. How a boy who'd never even seen a doctor became one of Africa's foremost experts in diabetes is a story of (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98 Lancet Diab Endocrinol
  Jansson Sigfrids F, Groop PH, Harjutsalo V. Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohort study. Lancet Diabetes Endocrinol 2022; 10: (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [Corrections] Correction to Lancet Diabetes Endocrinol 2021; 9: 575–85 Lancet Diab Endocrinol
  Harjutsalo V, Pongrac Barlovic D, Groop PH. Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study. Lancet Diabetes Endocrinol 2021; 9: 575–85. In table 2 of this Article, row 2 of (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 12:40
  [Articles] Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials - Adem Y Dawed, Andrea Mari, Andrew Brown, Timothy J McDonald, Lin Li, Shuaicheng Wang, Mun-Gwan Hong, Sapna Sharma, Neil R Robertson, Anubha Mahajan, Xuan Wang, Mark Walker, Stephen Gough, Leen M ‘t Hart, Kaixin Zhou, Ian Forgie, Hartmut Ruetten, Imre Pavo, Pallav Bhatnagar, Angus G Jones, Ewan R Pearson, DIRECT consortium Lancet Diab Endocrinol
  This genome-wide pharmacogenomic study of GLP-1 receptor agonists provides novel biological and clinical insights. Clinically, when genotype is routinely available at the point of prescribing, individuals with ARRB1 variants might benefit from earlier initiation of GLP-1 receptor (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

23 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [TimeCapsule] Glucagon, from past to present: a century of intensive research and controversies - André J Scheen, Pierre J Lefèbvre Lancet Diab Endocrinol
  2022 corresponds to the 100th anniversary of the discovery of glucagon. This TimeCapsule aims to recall the main steps leading to the discovery, characterisation, and clinical importance of the so-called second pancreatic hormone. We describe the early historical findings in basic research (ie, (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))

20 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Analysis of cluster randomised trials as if they were individually randomised - Mark J Bolland, Alison Avenell, Andrew Grey Lancet Diab Endocrinol
  The meta-analysis by David A Jolliffeand colleagues,1 published in The Lancet Diabetes & Endocrinology, includes two cluster randomised controlled trials (RCTs) that were analysed as if they were individually randomised. This approach will overestimate the precision of the effect size for (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))
• 00:30
  [Correspondence] Analysis of cluster randomised trials as if they were individually randomised – Authors' reply - David A Jolliffe, Adrian R Martineau Lancet Diab Endocrinol
  We thank Mark Bolland and colleagues for their comments on our Article1 published in The Lancet Diabetes & Endocrinology. We did not pre-specify adjustment for clustering in our meta-analysis1 as the two trials in question2,3 contributed relatively little data to it. The letter from Bolland (...) (The Lancet Diabetes & Endocrinology 11, 2 (2023))

11 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Long-term bone health in childhood cancer survivors: underappreciated and undertreated? - Cornelia S Link-Rachner, Tilman D Rachner Lancet Diab Endocrinol
  Maintenance of bone quality is an ongoing challenge throughout the lifespan of a cancer survivor. Although bone metastases are the most obvious scenario in which a malignancy negatively affects bone, non-metastatic cancer can also impair bone metabolism by direct (eg, cancer mediated) or (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 00:30
  [Articles] Risk and determinants of low and very low bone mineral density and fractures in a national cohort of Dutch adult childhood cancer survivors (DCCSS-LATER): a cross-sectional study - Jenneke E van Atteveld, Demi T C de Winter, Vincent G Pluimakers, Marta Fiocco, Rutger A J Nievelstein, Monique G G Hobbelink, Andrica C H de Vries, Jacqueline J Loonen, Eline van Dulmen-den Broeder, Helena J van der Pal, Saskia M F Pluijm, Leontien C M Kremer, Cécile M Ronckers, Margriet van der Heiden-van der Loo, A Birgitta Versluijs, Marloes Louwerens, Dorine Bresters, Hanneke M van Santen, Daniel S Olsson, Imo Hoefer, Sjoerd A A van den Berg, Jaap den Hartogh, Wim J E Tissing, Sebastian J C M M Neggers, Marry M van den Heuvel-Eibrink, Dutch LATER study (...) Lancet Diab Endocrinol
  Survivors of childhood cancer are at increased risk of any first fracture. Very low lumbar spine BMD was associated with fractures, highlighting the importance of active BMD surveillance in high-risk survivors (ie, those treated with cranial, craniospinal, or total body irradiation). Moreover, (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

6 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 14:00
  [Review] Continuous glucose monitoring and metrics for clinical trials: an international consensus statement - Tadej Battelino, Charles M Alexander, Stephanie A Amiel, Guillermo Arreaza-Rubin, Roy W Beck, Richard M Bergenstal, Bruce A Buckingham, James Carroll, Antonio Ceriello, Elaine Chow, Pratik Choudhary, Kelly Close, Thomas Danne, Sanjoy Dutta, Robert Gabbay, Satish Garg, Julie Heverly, Irl B Hirsch, Tina Kader, Julia Kenney, Boris Kovatchev, Lori Laffel, David Maahs, Chantal Mathieu, Dídac Mauricio, Revital Nimri, Rimei Nishimura, Mauro Scharf, Stefano Del Prato, Eric Renard, Julio Rosenstock, Banshi Saboo, Kohjiro Ueki, Guillermo E Umpierrez, Stuart A Weinzimer, Moshe (...) Lancet Diab Endocrinol
  Randomised controlled trials and other prospective clinical studies for novel medical interventions in people with diabetes have traditionally reported HbA1c as the measure of average blood glucose levels for the 3 months preceding the HbA1c test date. The use of this measure highlights the (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

3 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] An inclusive approach to people with disabilities in diabetes care and education - Sze May Ng Lancet Diab Endocrinol
  All people with disabilities deserve dedicated and equitable health care. The UN Convention on the Rights of Persons with Disability states that people with disabilities have the right to enjoy the highest attainable standard of health without discrimination.1 People with learning and (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

2 December

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Diabetes after SARS-CoV-2 infection - Ziyad Al-Aly Lancet Diab Endocrinol
  The COVID-19 global pandemic represents a unique opportunity to better understand the post-viral and post-infectious condition. More than 2 years into the pandemic, a large body of evidence makes it clear that infection with SARS-CoV-2 can lead to post-acute sequelae in the pulmonary and broad (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

30 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The role of nurses in diabetes care: challenges and opportunities - Valla Tantayotai, Aida Abraimova, Sigiriya Aebischer Perone, Montserrat Castellsague Perolini, Bruno Lab, Altynai Mambetova, Luz Perrenoud, David Beran Lancet Diab Endocrinol
  With the global prevalence of diabetes set to increase over the coming decades from 537 million in 2021 to 783 million in 2045,1 solutions must be found to ensure that both prevention and treatment are guaranteed. A key component to this response will be the strengthening of health systems. (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))
• 00:30
  [Viewpoint] Treating chronic diseases without tackling excess adiposity promotes multimorbidity - Naveed Sattar, John J V McMurray, Iain B McInnes, Vanita R Aroda, Mike E J Lean Lancet Diab Endocrinol
  Few people now reach old age without taking multiple drugs, often attending various clinics, and undergoing secondary or tertiary investigations. Most chronic conditions are, to differing extents, caused or exacerbated by excess adiposity, but weight management is rarely discussed or attempted (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

26 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Re-evaluating obesity in Mexico—lessons for the global obesity epidemic - James René Jolin, Lauren Kim, Verónica Vázquez-Velázquez, Fatima Cody Stanford Lancet Diab Endocrinol
  Obesity is increasingly cited as the leading public health concern in Mexico.1 As Barquera and Rivera reported in The Lancet Diabetes & Endocrinology,1 Mexico has undergone a “rapid epidemiological transition,” with nationally representative surveys showing that obesity rates (BMI ?30 kg/m2) (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

25 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] FDA approves teplizumab: a milestone in type 1 diabetes - James S Hirsch Lancet Diab Endocrinol
  New therapies come slowly for type 1 diabetes, so the approval of teplizumab by the USA Food and Drug Administration (FDA) marks a milestone. The drug itself, a humanised anti-CD3 monoclonal antibody, delays clinical type 1 diabetes in at-risk individuals and is the first approved (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

15 November

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Country Focus] Osteoporosis in the USA: prevention and unmet needs - Sundeep Khosla, Nicole C Wright, Ann L Elderkin, Douglas P Kiel Lancet Diab Endocrinol
  The past 30 years have witnessed tremendous progress in our ability to diagnose and treat osteoporosis. Once considered an inevitable consequence of ageing, osteoporosis can now be accurately diagnosed using dual-energy x-ray absorptiometry (DXA). Fundamental advances in the understanding of (...) (The Lancet Diabetes & Endocrinology 11, 1 (2023))

1 August

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Comment] Blood glucose targets in the critically ill: is one size fits all still appropriate? - James S Krinsley, Michael Brownlee, Michael W Schwartz, Gregory Roberts, Jean-Charles Preiser, Peter Rule, Guillermo E Umpierrez, Irl B Hirsch Lancet Diab Endocrinol
  In 2001, the paradigm for blood glucose control in hospitalised patients was challenged by a single-centre, randomised controlled trial (RCT).1 Conducted in mechanically ventilated surgical intensive care unit (ICU) patients (970 [63%] of 1548 following cardiovascular surgery and 1344 [87%] (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:00
  [Correspondence] Perceptions of alternative methods of insulin storage: an ethical dilemma - Arunkumar R Pande, Ashwani Kumar Thakur Lancet Diab Endocrinol
  Efficient insulin storage and prevention of its degradation remains one of the sought-after goals for endocrinologists, molecular biologists, and protein scientists. We read with interest the In-Focus piece by Talha Burki on insulin thermostability in The Lancet Diabetes & Endocrinology.1 (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))

8 July

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] What's preventing us from curbing the obesity crisis? - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  In early June, 2022, when the SURMOUNT-1 trial reported over a 20% weight loss with tirzepatide an explosion of social media posts labelled the results as “unprecedented”, “phenomenal”, and “game-changing”. As obesity rates continue to rise worldwide and the burden of disease for individuals and (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))

6 July

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] On the road to universal screening for risk of type 1 diabetes - Maria J Redondo Lancet Diab Endocrinol
  In this issue of The Lancet Diabetes & Endocrinology, Mohamed Ghalwash and colleagues1 sought to determine the optimal age or ages for islet-autoantibody screening to predict the development of clinical type 1 diabetes by 15 years of age. The authors combined five birth cohorts (from the (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:30
  [Articles] Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study - Mohamed Ghalwash, Jessica L Dunne, Markus Lundgren, Marian Rewers, Anette-G Ziegler, Vibha Anand, Jorma Toppari, Riitta Veijola, William Hagopian, Type 1 Diabetes Intelligence Study Group Lancet Diab Endocrinol
  Our results show that initial screening for islet autoantibodies at two ages (2 years and 6 years) is sensitive and efficient for public health translation but might require adjustment by country on the basis of population-specific disease (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))

2 July

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] World Health Assembly ratifies first global diabetes targets - Emma Wilkinson Lancet Diab Endocrinol
  Global coverage targets for diabetes have been agreed for the first time by WHO member states during the 75th World Health Assembly (WHA) to tackle rising prevalence and inequities in access to treatment and care. (The Lancet Diabetes & Endocrinology 10, 8 (2022))

1 July

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Impact of BMI on COVID-19 vaccine effectiveness - Annelies Wilder-Smith, Annika Frahsa Lancet Diab Endocrinol
  COVID-19 and obesity are two overlapping pandemics.1 Individuals with obesity are at risk of developing more severe clinical outcomes as a result of SARS-CoV-2 infection than those without obesity.2,3 Obesity is also associated with known risk factors for severe COVID-19, such as diabetes and (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:30
  [Articles] Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance - Ross Hamblin, Ashley Vardon, Josephine Akpalu, Metaxia Tampourlou, Ioannis Spiliotis, Emilia Sbardella, Julie Lynch, Vani Shankaran, Akash Mavilakandy, Irene Gagliardi, Sara Meade, Claire Hobbs, Alison Cameron, Miles J Levy, John Ayuk, Ashley Grossman, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Narendra Reddy, Karin Bradley, Robert D Murray, Aparna Pal, Niki Karavitaki Lancet Diab Endocrinol
  Irradiated adults with pituitary adenoma or craniopharyngioma are at increased risk of second brain tumours, although this risk is considerably lower than previously reported in studies using general population controls with no imaging surveillance. Our data clarify an important clinical (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:30
  [Comment] Second brain tumours after pituitary irradiation: lower risk than once thought - Luigi Maione, Philippe Chanson Lancet Diab Endocrinol
  Since its first proposal in the treatment of pituitary tumours more than a century ago, indications for cranial radiotherapy have notably evolved. In rare pituitary carcinomas, indication of radiotherapy remains undisputable after surgical treatment in case of remnant tumour or recurrence. (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:30
  [Articles] Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study - Carmen Piernas, Martina Patone, Nerys M Astbury, Min Gao, Aziz Sheikh, Kamlesh Khunti, Manu Shankar-Hari, Sharon Dixon, Carol Coupland, Paul Aveyard, Julia Hippisley-Cox, Susan A Jebb Lancet Diab Endocrinol
  Using BMI categories, there is evidence of protection against severe COVID-19 in people with overweight or obesity who have been vaccinated, which was of a similar magnitude to that of people of healthy weight. Vaccine effectiveness was slightly lower in people with underweight, in whom vaccine (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:00
  [Series] Diagnosis of thyroid nodules - Erik K Alexander, Edmund S Cibas Lancet Diab Endocrinol
  Thyroid nodules are common, usually asymptomatic, and often pose minimal risk to the affected patient. However, 10–15% prove malignant and serve as the rationale for diagnostic assessment. Safely identifying and treating a relevant thyroid cancer through a cost-effective process is the primary (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:00
  [Series] Management of thyroid nodules - Erik K Alexander, Gerard M Doherty, Justine A Barletta Lancet Diab Endocrinol
  In the past 30 years, there has been a substantial rise in the detection of thyroid nodules. Largely asymptomatic, thyroid nodules are most often incidental findings that typically pose minimal risk. Data supporting these findings show a rapid rise in the incidental detection of thyroid nodules (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

23 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Banning junk food ads: commitment waning in the UK? - Talha Burki Lancet Diab Endocrinol
  On May 14, 2022, the UK government announced it would delay imple-menting key components of its obesity strategy. A 2100 h watershed, before which certain categories of food and drink high in fat, salt, or sugar (HFSS) could not be advertised on television, had been due to come into effect in (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:30
  [Correction] Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17 Lancet Diab Endocrinol
  Battelino T, Bergenstal RM, Rodríguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))

18 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Type 1 diabetes in diverse ancestries and the use of genetic risk scores - Maria J Redondo, Christopher R Gignoux, Dana Dabelea, William A Hagopian, Suna Onengut-Gumuscu, Richard A Oram, Stephen S Rich Lancet Diab Endocrinol
  Over 75 genetic loci within and outside of the HLA region influence type 1 diabetes risk. Genetic risk scores (GRS), which facilitate the integration of complex genetic information, have been developed in type 1 diabetes and incorporated into models and algorithms for classification, prognosis, (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))

9 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Prioritising COVID-19 over everything: the unintended harm - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  During the past 2 and a half years, countries worldwide saw disruptions in their health-care services as they redirected their efforts and resources to manage the COVID-19 pandemic. At the same time, many people with underlying conditions limited their interactions with others unless necessary, (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

2 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] How should endocrinologists diagnose and treat non-alcoholic fatty liver disease? - Christopher D Byrne, Giovanni Targher Lancet Diab Endocrinol
  Non-alcoholic fatty liver disease (NAFLD) was first described in 1980 in a report from the Mayo Clinic that described the characteristics of non-alcoholic steatohepatitis in 20 patients.1 A liver biopsy showed “the presence of striking fatty changes with evidence of lobular hepatitis, focal (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [In Focus] Diabetes in humanitarian crises - Talha Burki Lancet Diab Endocrinol
  As of May 31, 2022, an estimated 14 million Ukrainians had fled their homes since the Russia invasion earlier in the year. There are no guarantees that they will be able to return anytime soon. Refugees commonly spend years, sometimes decades, away from home. The war in Ukraine has pushed the (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Correspondence] Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome - Louise Grahnemo, Maria Nethander, Eivind Coward, Maiken Elvestad Gabrielsen, Satya Sree, Jean-Marc Billod, Lars Engstrand, Sanna Abrahamsson, Arnulf Langhammer, Kristian Hveem, Claes Ohlsson Lancet Diab Endocrinol
  It is well established that the gut microbiota influences obesity in mice. In humans, some gut microbes have been associated with obesity, 1,2 but results have been difficult to replicate, proposedly due to small studies and confounders.3,4 Insufficient control over medication use can interfere (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [In Focus] Europe's obesity burden on the rise: WHO report - Vijay Shankar Balakrishnan Lancet Diab Endocrinol
  According to a report from WHO's Regional Office for Europe, released on May 3, 2022, the European region (comprising 53 countries in Europe and Central Asia) exhibits rates of overweight and obesity that are close to those in the Americas. “Obesity knows no borders [and] in Europe and Central (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

1 June

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Olivier Chabre, Marie Muller, Justine Cristante, Jean-Luc Cracowski, Emmanuel Gay Lancet Diab Endocrinol
  We read with interest the consensus statement of the Pituitary Society on diagnosis and management of Cushing's disease,1 which provides very useful new recommendations, including on neurosurgical or medical treatment of Cushing's disease. We have a comment on table 2, which summarises the (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:00
  [Correspondence] Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply - Maria Fleseriu, Frederic Castinetti, Mônica Gadelha, Andrea Giustina, André Lacroix, Shlomo Melmed, John Newell-Price, Rosario Pivonello, Martin Reincke, Beverly M K Biller, “Consensus on diagnosis and management of Cushing's disease: a guideline update” Lancet Diab Endocrinol
  We thank Olivier Chabre and colleagues for their thoughtful comments on our Review.1 (The Lancet Diabetes & Endocrinology 10, 6 (2022))

28 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The effect of COVID-19 on routine diabetes care and mortality in people with diabetes - David Hopkins, Francesco Rubino Lancet Diab Endocrinol
  The COVID-19 pandemic has had a disproportionate effect on the health of people living with diabetes. SARS CoV-2 affects many aspects of metabolism, creating the potential for biological interplay and bidirectional negative influence.1 Data from many countries have consistently shown that (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:30
  [Articles] Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study - Jonathan Valabhji, Emma Barron, Tessa Gorton, Chirag Bakhai, Partha Kar, Bob Young, Kamlesh Khunti, Naomi Holman, Naveed Sattar, Nicholas J Wareham Lancet Diab Endocrinol
  Our results show an increased risk of mortality in those who did not receive all eight care processes in one or both of the previous two years. Our results provide evidence that the increased rate of non-COVID-19-related mortality in people with diabetes in England observed between July 3, and (...) (The Lancet Diabetes & Endocrinology 10, 8 (2022))
• 00:30
  [In Focus] Treating diabetes: combining tradition and science - Manjulika Das Lancet Diab Endocrinol
  In April, 2022, the foundation stone of the WHO Global Centre for Traditional Medicine, the first and only global outpost centre in the world for traditional medicine, was laid by the Prime Minister of India, Narendra Modi, in Jamnagar, Gujarat, India. Others in attendance included the Indian (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

27 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Sylvia Kehlenbrink: facing the extremes - Carl Power Lancet Diab Endocrinol
  Managing a non-communicable disease (NCD) like diabetes is hard enough in a country with good health care. It is much more difficult where resources are scarce. Add a conflict, a natural disaster, or a humanitarian crisis, and a perfectly treatable illness can become an implacable agent of (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

17 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] The current state of clinical islet transplantation - Rainer W G Gruessner Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Braulio Marfil-Garza and colleagues report 20-year outcomes after islet transplantation in a large cohort study.1 It is yet another landmark study by the Edmonton group. In 2000, the so-called Edmonton protocol ushered in a new era in islet (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Articles] Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada - Braulio A Marfil-Garza, Sharleen Imes, Kevin Verhoeff, Joshua Hefler, Anna Lam, Khaled Dajani, Blaire Anderson, Doug O'Gorman, Tatsuya Kin, David Bigam, Peter A Senior, A M James Shapiro Lancet Diab Endocrinol
  We present the largest single-centre cohort study of long-term outcomes following islet transplantation. Although some limitations with our study remain, such as the retrospective component, a relatively small sample size, and the absence of non-transplant controls, we found that the combined (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

14 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Bone fragility in type 1 diabetes: new insights and future steps - Nicola Napoli, Caterina Conte Lancet Diab Endocrinol
  Bone fragility is a recognised complication of type 1 diabetes.1 People with type 1 diabetes have lower bone mineral density (BMD) and greater fracture risk than individuals without diabetes (more than five times for hip fracture and two times for non-vertebral fractures).2 The mechanisms (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Articles] Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study - Ann V Schwartz, Jye-Yu C Backlund, Ian H de Boer, Mishaela R Rubin, Annette Barnie, Kaleigh Farrell, Victoria R Trapani, Naina Sinha Gregory, Amisha Wallia, Ionut Bebu, John M Lachin, Barbara H Braffett, Rose Gubitosi-Klug, the DCCT/EDIC Research Group Lancet Diab Endocrinol
  Poorer glycaemic control, AGE accumulation, and kidney disease are independent risk factors for lower hip BMD in older adults with type 1 diabetes. Maintenance of glycaemic control and prevention of kidney disease might reduce bone loss and ultimately fractures in this population. Osteoporosis (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

7 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Is autonomous cortisol secretion sexually dimorphic? - Riccardo Pofi, Jeremy W Tomlinson Lancet Diab Endocrinol
  There is no doubt that exposure to chronic, substantially elevated circulating cortisol levels increases morbidity and mortality, as shown by patients with established Cushing's syndrome.1 Adrenal adenomas are common and are often detected incidentally in apparently asymptomatic individuals. (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Articles] Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study - Timo Deutschbein, Giuseppe Reimondo, Guido Di Dalmazi, Irina Bancos, Jekaterina Patrova, Dimitra Argyro Vassiliadi, Anja Bara? Neki?, Miguel Debono, Pina Lardo, Filippo Ceccato, Luigi Petramala, Alessandro Prete, Iacopo Chiodini, Miomira Ivovi?, Kalliopi Pazaitou-Panayiotou, Krystallenia I Alexandraki, Felicia Alexandra Hanzu, Paola Loli, Serkan Yener, Katharina Langton, Ariadni Spyroglou, Tomaz Kocjan, Sabina Zacharieva, Nuria Valdés, Urszula Ambroziak, Mari Suzuki, Mario Detomas, Soraya Puglisi, Lorenzo Tucci, Danae Anastasia Delivanis, Dimitris Margaritopoulos, Tina Dusek, Roberta (...) Lancet Diab Endocrinol
  Cortisol autonomy is associated with increased all-cause mortality, particularly in women younger than 65 years. However, until results from randomised interventional trials are available, a conservative therapeutic approach seems to be justified in most patients with adrenal (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

6 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Series] Management of menopause: a view towards prevention - Roger A Lobo, Anne Gompel Lancet Diab Endocrinol
  Women spend approximately one-third of their lives with menopause, which occurs around 50 years of age. It is now appreciated that several important metabolic and cardiovascular disease risks emerge during the menopausal transition. Many important conditions occur 10–15 years after menopause, (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Editorial] Menopause: a turning point for women's health - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Rising demand for menopausal hormone therapy (MHT) in the UK has resulted in shortages of some products, as suppliers struggle to keep up with demand. A consequence of increasing awareness of menopause symptoms and treatment options among women, prescriptions for MHT in England have doubled in (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

5 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 12:30
  [Series] Menopause: a cardiometabolic transition - Rossella E Nappi, Peter Chedraui, Irene Lambrinoudaki, Tommaso Simoncini Lancet Diab Endocrinol
  Menopause is often a turning point for women's health worldwide. Increasing knowledge from experimental data and clinical studies indicates that cardiometabolic changes can manifest at the menopausal transition, superimposing the effect of ageing onto the risk of cardiovascular disease. The (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [In Focus] Hot topics on insulin access: the issue of thermostability - Talha Burki Lancet Diab Endocrinol
  Some 770 million people around the world do not have access to electricity. In the sprawling Democratic Republic of Congo, less than 9% of the population is on the energy grid; a third of rural households in Bangladesh are not connected to the power supply; and neighbouring Myanmar provides (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

1 May

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Methodological considerations in D-health cancer mortality results - Sam Egger, David P Smith, Visalini Nair-Shalliker Lancet Diab Endocrinol
  We thank Rachel Neale and colleagues1 for their publication of the D-health Trial results in The Lancet Diabetes & Endocrinology, and commend their efforts in conducting a large, population-based trial of vitamin D3 supplementation. We do, however, have some concerns about the cancer (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:00
  [Correspondence] Methodological considerations in D-health cancer mortality results – Authors' reply - Rachel E Neale, Briony Duarte Romero, Donald S A McLeod, Dallas R English, Gunter Hartel, Jolieke C van der Pols, Alison J Venn, Penelope M Webb, David C Whiteman, Mary Waterhouse Lancet Diab Endocrinol
  We thank Sam Egger and colleagues for their interest in the results of the D-Health Trial.1 These authors raised the concern that missing underlying cause of death data could have biased our cancer mortality findings, and urged caution in drawing conclusions at this (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

28 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohort study - Fanny Jansson Sigfrids, Per-Henrik Groop, Valma Harjutsalo Lancet Diab Endocrinol
  Our analyses show that the cumulative incidence of severe albuminuria has decreased between 1970–79 and 1980–99; however, whether this decrease solely denotes a delay in albuminuria, or also a true prevention of albuminuria, needs to be investigated further. Nevertheless, diabetic kidney disease (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))
• 00:30
  [Comment] The uncomfortable truth about kidney disease in type 1 diabetes - Bruce A Perkins Lancet Diab Endocrinol
  Decades ago, the renowned epidemiologists Andrzej Krolewski and James Warram, together with colleagues, drew attention to an uncomfortable truth: shockingly, even 50 years after the discovery of life-saving insulin, more than half of people diagnosed with type 1 diabetes died with kidney (...) (The Lancet Diabetes & Endocrinology 10, 7 (2022))

27 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer - Furio Pacini Lancet Diab Endocrinol
  Since the first demonstration by Mazzaferri and colleagues1 that the administration of radioiodine therapy after total thyroidectomy for differentiated thyroid cancer reduced mortality and recurrences, such treatment strategy became the standard of care for patients with thyroid cancer. At that (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

26 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Country Focus] Singapore's “War on Diabetes” - Yong Mong Bee, E Shyong Tai, Tien Y Wong Lancet Diab Endocrinol
  In 2016, in the face of an impending diabetes epidemic, Singapore started a new strategic campaign, announced by the then Minister of Health in a parliamentary speech, which was referred to as the “War on Diabetes”.1 This campaign sought to rally the entire nation to rein in the diabetes and (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

23 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial - Tadej Battelino, Richard M Bergenstal, Angel Rodríguez, Laura Fernández Landó, Ross Bray, Zhentao Tong, Katelyn Brown Lancet Diab Endocrinol
  Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Articles] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial - Tim Heise, Andrea Mari, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Tamer Coskun, Melissa K Thomas, Kieren J Mather, Axel Haupt, Zvonko Milicevic Lancet Diab Endocrinol
  The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely ?-cell function, insulin sensitivity, and glucagon secretion. These effects were large and help to explain the remarkable (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] Tirzepatide adds hepatoprotection to its armoury - Giovanni Targher Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Amalia Gastaldelli and colleagues1 present their findings from SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial.2 It is the first study to date to assess the effect of a 52-week treatment with (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] SURPASSing the current dogma: is our framework shifting? - Natasha P Malkani, Vanita R Aroda Lancet Diab Endocrinol
  In their article in The Lancet Diabetes and Endocrinology, Tadej Battelino and colleagues1 report on a dedicated substudy of the parent SURPASS-3 randomised clinical trial, in which all three groups given the dual GLP-1 and GIP, tirzepatide (5 mg, 10 mg, or 15 mg weekly doses), had (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] Add-on value of tirzepatide versus semaglutide - André J Scheen Lancet Diab Endocrinol
  Type 2 diabetes is a complex disease with several key defects, including impaired insulin secretion, increased glucagon secretion, and insulin resistance, which is exacerbated by obesity. Thus, besides lifestyle measures, pharmacological therapy should aim to target most, if not all, of these (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Articles] Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial - Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, Ross Bray, Bram Brouwers, Ángel Rodríguez Lancet Diab Endocrinol
  Tirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study. These data provide additional evidence on the metabolic effects of this novel dual GIP and GLP-1 receptor (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

22 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study - Ranjit Mohan Anjana, Ranjit Unnikrishnan, Mohan Deepa, Ulagamathesan Venkatesan, Rajendra Pradeepa, Shashank Joshi, Banshi Saboo, Ashok Kumar Das, Sarita Bajaj, Anil Bhansali, Sri Venkata Madhu, Vinay Kumar Dhandhania, Puthiyaveettil Kottayam Jabbar, Sunil M Jain, Arvind Gupta, Subhankar Chowdhury, Mohammed K Ali, Elangovan Nirmal, Radhakrishnan Subashini, Tanvir Kaur, Rupinder Singh Dhaliwal, Nikhil Tandon, Viswanathan Mohan, ICMR-INDIAB collaborators Lancet Diab Endocrinol
  Achievement of treatment targets and adoption of healthy behaviours remains suboptimal in India. Our results can help governments to adopt policies that prioritise improvement of diabetes care delivery and surveillance in India. (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] The ABC targets of diabetes in India - Jennifer Manne-Goehler Lancet Diab Endocrinol
  In April 2021, WHO announced the creation of a Global Diabetes Compact (GDC) initiative to address the increasingly urgent global diabetes epidemic. GDC aims to catalyse action on diabetes and specifically seeks to “boost efforts to prevent diabetes and bring treatment to all who need it.”1 To (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
• 00:30
  [Comment] Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care - David E Sandberg, Eric Vilain Lancet Diab Endocrinol
  “We now know this approach [early genital surgery] was harmful and wrong.”1 Two major US children's hospitals (Lurie Children's Hospital, Chicago, IL, and Boston Children's Hospital, Boston, MA) announced a suspension of some elective genital surgeries, particularly clitoroplasty. This (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

8 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Long COVID: the elephant in the room - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  On April 1, 2022, the UK government ended free universal COVID-19 testing, as part of the Living with COVID-19 plan. The legal requirement to isolate if positive has also been scrapped in England under this plan, and all other public health restrictions have now been (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

6 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] War in Ukraine ups demand for iodine pills - Talha Burki Lancet Diab Endocrinol
  An unexpected consequence of the Russian invasion of Ukraine, which began on Feb 24, 2022, has been the surge in demand for iodine pills in many European countries and others further afield. Online vendors have been selling tablets of potassium iodide, the salt of stable iodine, for twice their (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))

2 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Targeting PCSK9 inhibitors to those who will benefit most - Traci A Turner, Evan A Stein Lancet Diab Endocrinol
  In The Lancet Diabetes & Endocrinology, Petr Ostadal and colleagues report a post-hoc subgroup analysis of the ODYSSEY OUTCOMES trial assessing the contribution of metabolic risk factors to future cardiovascular events in patients with recent acute coronary syndrome.1 This large (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] Dapagliflozin in young people with type 2 diabetes - Kalie L Tommerdahl, Robert G Nelson, Petter Bjornstad Lancet Diab Endocrinol
  The trial data presented by William V Tamborlane and colleagues, evaluating the effects of a novel adjunctive type 2 diabetes medication in young people (aged 18–24), provide an important therapeutic insight into this burgeoning, high-risk, and understudied population.1 Nearly 14 million people (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] Breakthrough technology for in-hospital glucose monitoring - David Kerr, David Klonoff Lancet Diab Endocrinol
  75 years ago, the English physician and writer, Richard Asher, highlighted the physical and mental health risks associated with an admission to hospital.1 For people living with diabetes, they have both an increased risk of being admitted to hospital, and, once admitted, are likely to spend (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Articles] Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial - Petr Ostadal, Philippe Gabriel Steg, Yann Poulouin, Deepak L Bhatt, Vera A Bittner, Terrence Chua, Rafael Diaz, Shaun G Goodman, Yong Huo, Johan Wouter Jukema, Yuri Karpov, Robert Pordy, Michel Scemama, Michael Szarek, Harvey D White, Gregory G Schwartz, ODYSSEY OUTCOMES Investigators Lancet Diab Endocrinol
  Accumulation of metabolic risk factors was associated with higher risk of MACE in patients with recent acute coronary syndrome. Alirocumab reduced MACE consistently, but aRR increased with number of metabolic risk factors. (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Articles] Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study - William V Tamborlane, Lori M Laffel, Naim Shehadeh, Elvira Isganaitis, Michelle Van Name, Jayantha Ratnayake, Cecilia Karlsson, Ensio Norjavaara Lancet Diab Endocrinol
  The primary outcome of change in HbA1c concentration was not significant in the intention-to-treat analysis of children, adolescents, and young adults with type 2 diabetes receiving dapagliflozin in addition to standard-of-care treatment. A prespecified sensitivity analysis of (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

1 April

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:00
  [Correspondence] Data processing in the DMagic cluster randomised controlled trial - Edward Fottrell, Carina King, Kishwar Azad, on behalf of the DMagic Trial Team Lancet Diab Endocrinol
  Our Article1 in The Lancet Diabetes & Endocrinology provides evidence on the effectiveness of mHealth and Participatory Learning and Action (PLA) community mobilisation interventions for reducing population-level prevalence of intermediate hyperglycaemia and type 2 diabetes and the (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2020; 8: 594–605 Lancet Diab Endocrinol
  Groeneweg S, van Geest FS, Abac? A, et al. Disease characteristics of MCT8 deficiency: an international, retrospective, multicentre cohort study. Lancet Diabetes Endocrinol 2020; 8: 594–605—In this Article, Gautam P Ambegaonkar's name was spelt incorrectly. This correction has been made to the (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:00
  [Corrections] Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28 Lancet Diab Endocrinol
  Neale RE, Baxter C, Duarte Romero B, et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. Lancet Diabetes Endocrinol 2022; 10: 120–28—In order to comply with requirements not to report small numbers of cases (n < 5), table S5 of the appendix of this (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

29 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Country Focus] Diabetes in Pakistan: addressing the crisis - Zulfiqar A Bhutta, Zia Ul Haq, Abdul Basit Lancet Diab Endocrinol
  Population-based estimates for both type 1 and type 2 diabetes in low-income and middle-income countries are imprecise because of the paucity of registration and surveillance systems in these settings. Current estimates for diabetes prevalence are largely derived from the Global Burden of (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

26 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Correspondence] Caring for people with diabetes and non-communicable diseases in Ukraine: a humanitarian emergency - Galyna Maystruk, Sigiriya Aebischer Perone, Valentyna Anufriyeva, Philippa Boulle, François Chappuis, Bruno Lab, David Beran Lancet Diab Endocrinol
  As war in Europe becomes a reality with the armed conflict in Ukraine, the global community has responded politically and economically, and is in the midst of preparing an large-scale humanitarian response. The first response needs to reach individuals who are directly affected by the conflict (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

22 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Rising diabetes diagnosis in long COVID - K M Venkat Narayan, Lisa R Staimez Lancet Diab Endocrinol
  A few reports have raised the possibility that COVID-19 could increase the risk of type 2 diabetes.1,2 In The Lancet Diabetes & Endocrinology, Xie and Al-Aly3 offer further evidence for the increased risk of diabetes beyond the first 30 days of infection (post-acute phase) by analysing the (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Articles] Risks and burdens of incident diabetes in long COVID: a cohort study - Yan Xie, Ziyad Al-Aly Lancet Diab Endocrinol
  In the post-acute phase, we report increased risks and 12-month burdens of incident diabetes and antihyperglycaemic use in people with COVID-19 compared with a contemporary control group of people who were enrolled during the same period and had not contracted SARS-CoV-2, and a historical (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

15 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial - Myrthe M van Dijk, Rosa Vissenberg, Eric Fliers, Joris A M van der Post, Marie-Louise P van der Hoorn, Sabina de Weerd, Walter K Kuchenbecker, Annemieke Hoek, J Marko Sikkema, Harold R Verhoeve, Kimiko A Broeze, Corry H de Koning, Willem Verpoest, Ole B Christiansen, Carolien Koks, Jan P de Bruin, Dimitri N M Papatsonis, Helen Torrance, Madelon van Wely, Peter H Bisschop, Mariëtte Goddijn Lancet Diab Endocrinol
  Compared with placebo, levothyroxine treatment did not result in higher live birth rates in euthyroid women with recurrent pregnancy loss who were positive for TPO-Ab. On the basis of our findings, we do not advise routine use of levothyroxine in women who are TPO-Ab positive with recurrent (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss - Tim I M Korevaar, Rima Dhillon-Smith Lancet Diab Endocrinol
  Miscarriage matters. For couples who have a miscarriage, it is a devastating experience with major physical and psychological consequences that are often under—estimated or even trivialised.1 Combined with the major health-economic effect on a population level, this makes research into (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))

10 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Ukraine: diabetes on the front line - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  The crisis in Ukraine is evolving rapidly, with 2 million people estimated to have fled the country as of March 8 and many more facing unimaginable danger and uncertainty. Despite some advances made in Ukraine's attempts to transform and modernise its health system, Ukrainian citizens still (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

9 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Thank you to The Lancet Diabetes & Endocrinology clinical and statistical peer reviewers in 2021 - The Lancet Diabetes & Endocrinology Editors Lancet Diab Endocrinol
  Gail Adler (The Lancet Diabetes & Endocrinology 10, 4 (2022))

8 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Articles] The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020 - Margherita Pizzato, Mengmeng Li, Jerome Vignat, Mathieu Laversanne, Deependra Singh, Carlo La Vecchia, Salvatore Vaccarella Lancet Diab Endocrinol
  The current thyroid cancer epidemiological landscape is strongly suggestive of a large effect of overdiagnosis in many countries and settings worldwide, confirming the relevance of thyroid cancer overdiagnosis as a global public health (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Comment] Global thyroid estimates in 2020 - Livia Lamartina, Sophie Leboulleux, Isabelle Borget, Martin Schlumberger Lancet Diab Endocrinol
  Since the early 1980s, the incidence rate of thyroid cancers is increasing in many countries, although changes in mortality rates have been minimal.1–3 Reported in The Lancet Diabetes and Endocrinology, Margherita Pizzato and colleagues'4 used the GLOBOCAN database to estimate age-standardised (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Comment] Women in diabetes research: stepping towards equity - Linda A DiMeglio, Jamie R Wood, Eda Cengiz Lancet Diab Endocrinol
  “Real change, enduring change, happens one step at a time.”Ruth Bader Ginsburg (The Lancet Diabetes & Endocrinology 10, 4 (2022))

5 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] From preeclampsia to thyroid dysfunction: a long and winding road - Francesco Vermiglio, Mariacarla Moleti Lancet Diab Endocrinol
  Hypertensive disorders of pregnancy, including gestational hypertension and preeclampsia or eclampsia, affect around 10% of pregnant women and are one of the leading causes of maternal and neonatal mortality and morbidity worldwide.1 In addition, women with hypertension during pregnancy are at (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Comment] Creating diabetes guidelines for the individual not just the illness - Nuha Ali El Sayed, Robert Gabbay, Guillermo E Umpierrez Lancet Diab Endocrinol
  For more than 30 years the American Diabetes Association (ADA) has developed and published recommendations and related documents for clinical practice for diabetes care. ADA's Standards of Medical Care in Diabetes document,1 referred to as the Standards of Care, is intended to inform (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Articles] Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis - Freddy J K Toloza, Arash Derakhshan, Tuija Männistö, Sofie Bliddal, Polina V Popova, David M Carty, Liangmiao Chen, Peter Taylor, Lorena Mosso, Emily Oken, Eila Suvanto, Sachiko Itoh, Reiko Kishi, Judit Bassols, Juha Auvinen, Abel López-Bermejo, Suzanne J Brown, Laura Boucai, Aya Hisada, Jun Yoshinaga, Ekaterina Shilova, Elena N Grineva, Tanja G M Vrijkotte, Jordi Sunyer, Ana Jiménez-Zabala, Isolina Riaño-Galan, Maria-Jose Lopez-Espinosa, Larry J Prokop, Naykky Singh Ospina, Juan P Brito, Rene Rodriguez-Gutierrez, Erik K Alexander, Layal Chaker, Elizabeth N Pearce, Robin P Peeters, Ulla (...) Lancet Diab Endocrinol
  Compared with euthyroidism, subclinical hypothyroidism during pregnancy was associated with a higher risk of pre-eclampsia. There was a U-shaped association of TSH with pre-eclampsia. These results quantify the risks of gestational hypertension or pre-eclampsia in women with thyroid function (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

4 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Obesity in children and adolescents: epidemiology, causes, assessment, and management - Hiba Jebeile, Aaron S Kelly, Grace O'Malley, Louise A Baur Lancet Diab Endocrinol
  This Review describes current knowledge on the epidemiology and causes of child and adolescent obesity, considerations for assessment, and current management approaches. Before the COVID-19 pandemic, obesity prevalence in children and adolescents had plateaued in many high-income countries (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:30
  [Comment] The actual burden of obesity—accounting for multimorbidity - Avishai M Tsur, Gilad Twig Lancet Diab Endocrinol
  The prevalence of overweight and obesity is increasing worldwide, and this is forecast to continue in the coming years. One in two adults in the USA are projected to have obesity by 2030, and about one in four to have severe obesity.1 Excessive weight has been causally linked to diabetes, (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))
• 00:30
  [Articles] Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study - Mika Kivimäki, Timo Strandberg, Jaana Pentti, Solja T Nyberg, Philipp Frank, Markus Jokela, Jenni Ervasti, Sakari B Suominen, Jussi Vahtera, Pyry N Sipilä, Joni V Lindbohm, Jane E Ferrie Lancet Diab Endocrinol
  Obesity is associated with diverse, increasing disease burdens, and might represent an important target for multimorbidity prevention that avoids the complexities of multitarget preventive regimens. (The Lancet Diabetes & Endocrinology 10, 4 (2022))

3 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Osteoporosis in men - Tatiane Vilaca, Richard Eastell, Marian Schini Lancet Diab Endocrinol
  Osteoporosis in men is a common but often overlooked disorder by clinicians. The criterion for osteoporosis diagnosis in men is similar to that in women—namely, a bone mineral density (BMD) that is 2·5 standard deviations or more below the mean for the young adult population (aged 20–29 years; (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

1 March

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Personal View] The relevance of T3 in the management of hypothyroidism - Domenico Salvatore, Tommaso Porcelli, Matthew D Ettleson, Antonio C Bianco Lancet Diab Endocrinol
  Levothyroxine monotherapy has been the standard of care for treatment of hypothyroidism for more than 40 years. However, patients treated with levothyroxine have relatively lower serum tri-iodothyronine (T3) concentrations than the general population, and symptoms of hypothyroidism persist for (...) (The Lancet Diabetes & Endocrinology 10, 5 (2022))
• 00:00
  [Correspondence] Dose–response relationships for vitamin D and all-cause mortality - Martin R Grübler, Heike A Bischoff-Ferrari, Stefan Pilz Lancet Diab Endocrinol
  The Emerging Risk Factors Collaboration/EPIC-CVD/Vitamin D Studies Collaboration1 report on a Mendelian meta-analysis of 500 962 participants, providing strong evidence that 25-hydroxyvitamin D (25[OH]D) concentrations below 40 nmol/L are causal for all-cause mortality. We congratulate the (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:00
  [Correspondence] Dose–response relationships for vitamin D and all-cause mortality – Authors' reply - Stephen Burgess, Adam S Butterworth Lancet Diab Endocrinol
  We would like to thank Martin Grübler and colleagues for their correspondence regarding our published Article.1 In response to the points raised, regarding the threshold of 25-hydroxyvitamin D (25[OH]D) concentration, we would not want to be overly dogmatic about the specific threshold below (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 102–11 Lancet Diab Endocrinol
  Fleseriu M, Dreval A, Bondar I, et al. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 2022; 10: 102–11—First, in the Discussion section (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

18 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] A global view of the interplay between non-alcoholic fatty liver disease and diabetes - Norbert Stefan, Kenneth Cusi Lancet Diab Endocrinol
  Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular disease. The pathophysiology of NAFLD, particularly involving insulin resistance and subclinical inflammation, is not only (...) (The Lancet Diabetes & Endocrinology 10, 4 (2022))

12 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Editorial] Homing in on the causes of male infertility - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  Affecting millions of men and women of reproductive age worldwide, infertility (defined as the failure to conceive after 12 months of regular, unprotected sexual intercourse) deprives people of those most personal of choices—when to start a family and how many children to have. In addition, (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Editorial] Childhood cancer survival: a gap in need of closing - The Lancet Diabetes & Endocrinology Lancet Diab Endocrinol
  With a child dying from cancer every 3 min and survival as low as 20% in many low-income and middle-income countries (LMICs)—compared with 80% in most high-income countries—the need for children and adolescents with cancer to have better access to care could not be more apparent or urgent. (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

9 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Data-driven type 2 diabetes patient clusters predict metabolic surgery outcomes - Jason Flannick Lancet Diab Endocrinol
  Optimism regarding precision medicine has increased in recent years, and type 2 diabetes provides one of its more promising applications.1 The large public health burden of type 2 diabetes is exacerbated by inadequate treatments, which might be better designed or deployed if the complex and (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Articles] Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study - Violeta Raverdy, Ricardo V Cohen, Robert Caiazzo, Helene Verkindt, Tarissa Beatrice Zanata Petry, Camille Marciniak, Benjamin Legendre, Pierre Bauvin, Estelle Chatelain, Alain Duhamel, Elodie Drumez, Naima Oukhouya-Daoud, Mikael Chetboun, Gregory Baud, Emma Ahlqvist, Niels Wierup, Olof Asplund, Blandine Laferrère, Leif Groop, FranÇois Pattou Lancet Diab Endocrinol
  Patients in the SIRD subgroup had better outcomes after metabolic surgery, both in terms of type 2 diabetes remission and renal function, with no additional surgical risk. Data-driven classification might help to refine the indications for metabolic (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

8 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [InFocus] Lebanon: insulin out of reach after subsidies lifted - Manjulika Das Lancet Diab Endocrinol
  People with diabetes face a critical situation in Lebanon, thanks to a substantial price hike of insulin. (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Comment] Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care - Henrik Toft Sørensen Lancet Diab Endocrinol
  Diabetes is one of the fastest growing chronic diseases in the world, with major effects on both people with diabetes and wider society. In 2019, worldwide diabetes prevalence was estimated at 9·3%.1 Although the global diabetes pandemic is largely due to type 2 diabetes, the incidence of type 1 (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Correspondence] An inter-humanitarian agency study of diabetes care and surveillance in humanitarian settings - Sylvia Kehlenbrink, Omar Mahboob, Sara Al-Zubi, Philippa Boulle, Sigiriya Aebischer Perone, Ahmad Hecham Alani, Lilian Kiapi, Laura Miller, Heiko Hering, Michael Woodman, Karen Donelan, Stephanie Kayden, Bianca C Porneala, Bernard Rosner, James B Meigs Lancet Diab Endocrinol
  Humanitarian crises and diabetes have been increasing at an unrelenting pace, especially in low-income and middle-income countries.1 Over 80% of the global displaced population live in low-income and middle-income countries, which host 81% of the global diabetes population.2 Furthermore, for (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Articles] Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019 - GBD 2019 Diabetes Mortality Collaborators Lancet Diab Endocrinol
  Decreasing diabetes mortality at ages younger than 25 years remains an important challenge, especially in low and low-middle SDI countries. Inadequate diagnosis and treatment of diabetes is likely to be major contributor to these early deaths, highlighting the urgent need to provide better (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

5 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Comment] Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia - Tricia M-M Tan, Bernard Khoo Lancet Diab Endocrinol
  Obesity is a global disease and is particularly prevalent in Asia. 1 billion people across Asia are estimated to have a BMI exceeding 25 kg/m2.1 Obesity affects one in three Chinese individuals, with a marked increase observed in the past 15 years,2 this trend has also been observed in other (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:30
  [Articles] Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial - Takashi Kadowaki, Joakim Isendahl, Usman Khalid, Sang Yeoup Lee, Tomoyuki Nishida, Wataru Ogawa, Kazuyuki Tobe, Toshimasa Yamauchi, Soo Lim, STEP 6 investigators Lancet Diab Endocrinol
  Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

3 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Jennifer Manne-Goehler: at the crossroads of pandemics - Ray Cavanaugh Lancet Diab Endocrinol
  Increased awareness and distribution of antiretroviral treatments have tempered the catastrophe wrought by HIV/AIDS. But the same regions which suffered the heaviest HIV burden are now contending with a more recent public health crisis in the form of cardiovascular and metabolic diseases. The (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

2 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [In Focus] Managing Diabetes and Homelessness - Talha Burki Lancet Diab Endocrinol
  It is difficult to overstate how complicated life becomes when you have nowhere to live. It is a situation increasing numbers of Londoners find themselves in. According to a new analysis by Shelter, a charity that campaigns to end homelessness and poor housing in the UK, 700 people sleep on the (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))

1 February

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Personal View] Sexual dimorphism in COVID-19: potential clinical and public health implications - Nicole Bechmann, Andreas Barthel, Andreas Schedl, Stephan Herzig, Zsuzsanna Varga, Catherine Gebhard, Manuel Mayr, Constanze Hantel, Felix Beuschlein, Christian Wolfrum, Nikolaos Perakakis, Lucilla Poston, Cynthia L Andoniadou, Richard Siow, Raul R Gainetdinov, Arad Dotan, Yehuda Shoenfeld, Geltrude Mingrone, Stefan R Bornstein Lancet Diab Endocrinol
  Current evidence suggests that severity and mortality of COVID-19 is higher in men than in women, whereas women might be at increased risk of COVID-19 reinfection and development of long COVID. Differences between sexes have been observed in other infectious diseases and in the response to (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))
• 00:00
  [Corrections] Correction to Lancet Diabetes Endocrinol 2022; 10: 142–48 Lancet Diab Endocrinol
  Lewis GF, Hegele RA. Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes Endocrinol 2022; 10: 142–48—In the figure of this Personal View, the fifth bullet point should read “Treatment of diabetes…”. This correction has been made (...) (The Lancet Diabetes & Endocrinology 10, 2 (2022))

29 January

Lancet Diab Endocrinol https://www.thelancet.com/journals/landia/home

• 00:30
  [Review] Bone fragility in diabetes: novel concepts and clinical implications - Lorenz C Hofbauer, Björn Busse, Richard Eastell, Serge Ferrari, Morten Frost, Ralph Müller, Andrea M Burden, Fernando Rivadeneira, Nicola Napoli, Martina Rauner Lancet Diab Endocrinol
  Increased fracture risk represents an emerging and severe complication of diabetes. The resulting prolonged immobility and hospitalisations can lead to substantial morbidity and mortality. In type 1 diabetes, bone mass and bone strength are reduced, resulting in up to a five-times greater risk (...) (The Lancet Diabetes & Endocrinology 10, 3 (2022))